Table 2.
Primary and secondary outcomes at day 28
| Unadjusted population | Weighted population | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TCZ | Control | p Value | HR [CI] | p Value | TCZ | Control | p Value | HR [CI] | p Value | ||
| N = 49 | N = 47 | N = 49 | N = 47 | ||||||||
| Main outcomes at day 28 | |||||||||||
| Ventilatory support (all types) | 22 (44.9) | 40 (85.1) | < 0.001 | 0.41 [0.24–0.68] | 0.001 | 49.3% | 89.0% | < 0.001 | 0.39 [0.25–0.56] | < 0.001 | |
| Invasive mechanical ventilation | 15 (30.6) | 19 (40.4) | 0.315 | 0.67 [0.34–1.32] | 0.252 | 30.9% | 45.1% | 0.046 | 0.58 [0.36–0.94] | 0.026 | |
| Death | 5 (10.2) | 6 (12.8) | 0.694 | 0.75 [0.22–2.48] | 0.632 | 11.7% | 15.9% | 0.405 | 0.68 [0.31–1.48] | 0.338 | |
| Oxygen withdrawal* | 37 (82.2) | 31 (75.6) | 0.451 | 1.57 [0.97–2.56] | 0.064 | 82.0% | 73.5% | 0.179 | 1.66 [1.17–2.37] | 0.005 | |
| Hospital discharge | 33 (75.0) | 23 (56.1) | 0.066 | 1.77 [1.04–3.06] | 0.034 | 70.2% | 40.1% | 0.009 | 1.82 [1.22–2.75] | 0.003 | |
| WHO ordinal 8-category scale at day 28 | OR [CI] | OR [CI] | |||||||||
| Ambulatory | WHO scale 2 | 2.15 [0.95–4.99] | 0.069 | 1.83 [1.02–3.29] | 0.041 | ||||||
| Ambulatory or hospitalized mild disease | WHO scale 2/3/4 | 1.70 [0.65–4.58] | 0.282 | 1.47 [0.75–2.91] | 0.258 | ||||||
| Hospitalized severe disease | WHO scale 5/6/7 | 0.51 [0.13–1.41] | 0.198 | 0.30 [0.10–0.79] | 0.020 | ||||||
WHO World Health Organization, HR hazard ratio, OR odd ratio, CI confidence interval, TCZ tocilizumab
Weighted proportions, HRs, ORs, and 95%CIs were obtained by inverse probability treatment weighting
*n = 85 patients (TCZ, n = 44; control, n = 41) as 11 patients died and were excluded from analysis for oxygen weaning